Cargando…

Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study

Inflammatory biomarkers have been associated with clinical outcomes in non-small cell lung cancer (NSCLC). However, the best prognostic marker(s) has not been identified, and the association between inflammatory markers and clinical characteristics is poorly understood. We selected 1,237 patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takada, Kazuki, Takamori, Shinkichi, Matsubara, Taichi, Haratake, Naoki, Akamine, Takaki, Kinoshita, Fumihiko, Ono, Yuki, Wakasu, Sho, Tanaka, Kensuke, Oku, Yuka, Oba, Taro, Osoegawa, Atsushi, Tagawa, Tetsuzo, Takenoyama, Mitsuhiro, Shimokawa, Mototsugu, Oda, Yoshinao, Mori, Masaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605706/ https://www.ncbi.nlm.nih.gov/pubmed/33137158 http://dx.doi.org/10.1371/journal.pone.0241580

Ejemplares similares

The significant influence of having children on the postoperative prognosis of patients with nonsmall cell lung cancer: A propensity score‐matched analysis
por: Takamori, Shinkichi, et al.
Publicado: (2018)

Prognostic value of postoperative decrease in serum albumin on surgically resected early-stage non-small cell lung carcinoma: A multicenter retrospective study
por: Kinoshita, Fumihiko, et al.
Publicado: (2021)

The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial–mesenchymal transition in resected lung adenocarcinoma
por: Matsubara, Taichi, et al.
Publicado: (2019)

Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study)
por: Takamori, Shinkichi, et al.
Publicado: (2021)

The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab
por: Matsubara, Taichi, et al.
Publicado: (2020)

(18)F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer
por: Takada, Kazuki, et al.
Publicado: (2019)

Relationship between consolidation tumor ratio and tumor‐infiltrating lymphocytes in small‐sized lung adenocarcinoma
por: Ono, Yuki, et al.
Publicado: (2022)

Development of artificial intelligence prognostic model for surgically resected non-small cell lung cancer
por: Kinoshita, Fumihiko, et al.
Publicado: (2023)

Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma
por: Takada, Kazuki, et al.
Publicado: (2019)

Pulmonary metastasis presenting as a ground glass opacity-like lesion with a thin-walled cavity: A case report
por: Haro, Akira, et al.
Publicado: (2019)

Metabolic characteristics of programmed cell death‐ligand 1‐expressing lung cancer on (18)F‐fluorodeoxyglucose positron emission tomography/computed tomography
por: Takada, Kazuki, et al.
Publicado: (2017)

Brain cavernous hemangioma mimicking radiation‐induced necrosis in a patient with non‐small cell lung cancer
por: Takamori, Shinkichi, et al.
Publicado: (2020)

Histological conversion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor: a case report
por: Miura, Naoko, et al.
Publicado: (2020)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients
por: Haratake, Naoki, et al.
Publicado: (2019)

The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors
por: Takada, Kazuki, et al.
Publicado: (2022)

Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma
por: Takamori, Shinkichi, et al.
Publicado: (2020)

Does short-term cessation of smoking before lung resections reduce the risk of complications?
por: Takenaka, Tomoyoshi, et al.
Publicado: (2020)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
por: Shimokawa, Mototsugu, et al.
Publicado: (2022)

Impact of the pretreatment prognostic nutritional index on the survival after first‐line immunotherapy in non‐small‐cell lung cancer patients
por: Oku, Yuka, et al.
Publicado: (2023)

Re: COVID-19 in patients with neuroendocrine neoplasms: Preliminary results of a worldwide survey (The INTENSIVE study)
por: Takada, Kazuki, et al.
Publicado: (2021)

Correspondence Regarding “Tolerability of Coronavirus Disease 2019 Vaccines BNT162b2 and mRNA-1273 in Patients With Thymic Epithelial Tumors”
por: Takada, Kazuki, et al.
Publicado: (2021)

Cohesion between pulmonary artery and bronchus after immune checkpoint inhibitor therapy in a lung cancer patient
por: Takamori, Shinkichi, et al.
Publicado: (2020)

Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non‐small‐cell lung cancer: Real‐world data from 86 173 patients
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Impact of Liver Metastasis on First-Line Immunotherapy in Stage IV Non-Small Cell Lung Cancer
por: Komiya, Takefumi, et al.
Publicado: (2023)

A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
por: Takada, Kazuki, et al.
Publicado: (2022)

Relationship between obstructive lung disease and non-small cell lung cancer
por: Akamine, Takaki, et al.
Publicado: (2020)

Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression
por: Takada, Kazuki, et al.
Publicado: (2017)

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
por: Akamine, Takaki, et al.
Publicado: (2018)

Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials
por: Takada, Kazuki, et al.
Publicado: (2022)

Prognostic impact of noninvasive areas in resected pathological stage IA lung adenocarcinoma
por: Kinoshita, Fumihiko, et al.
Publicado: (2023)

Skeletal muscle area predicts the outcomes of non-small-cell lung cancer after trimodality therapy
por: Watanabe, Kenji, et al.
Publicado: (2023)

Significance of spread through air spaces in early‐stage lung adenocarcinomas undergoing limited resection
por: Toyokawa, Gouji, et al.
Publicado: (2018)

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Clinical significance of part-solid lung cancer in the eighth edition TNM staging system
por: Okamoto, Tatsuro, et al.
Publicado: (2021)

Long-term complete response to gefitinib after treatment termination in a patient with recurrent post-operative EGFR-mutated lung adenocarcinoma: case report and literature review
por: Watanabe, Kenji, et al.
Publicado: (2021)

Uncommon features of surgically resected ALK-positive cavitary lung adenocarcinoma: a case report
por: Takamori, Shinkichi, et al.
Publicado: (2017)

Clinical significance of the combination of preoperative SUVmax and CEA in patients with clinical stage IA lung adenocarcinoma
por: Hashinokuchi, Asato, et al.
Publicado: (2022)

Correspondence Regarding “Sleeve Lobectomy After Neoadjuvant Chemoimmunotherapy Versus Chemotherapy for Squamous Cell Lung Cancer: A Multicenter, Retrospective Study”
por: Takada, Kazuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4lcs8cb916toclcvvfdq51h3al